摘要
近年来,免疫检查点抑制剂在肿瘤患者的治疗中取得了极大进展,延长了肿瘤患者的生存期。免疫检查点抑制剂通过激活体内免疫细胞活性达到抗肿瘤目的,然而,在其扩大免疫抗肿瘤的同时也造成了一系列免疫毒性作用,其中免疫性心肌炎以高病死率引起了人们的重视。本综述总结了PD-1免疫检查点抑制剂相关性心肌炎的流行病学、发病机制、预测治疗反应的新型特异性生物标志物及其诊断。
In recent years,immune checkpoint inhibitors(ICIs)have made great progress in the treatment of cancer,prolonging the survival of the patients.Immune checkpoint inhibitors achieve the purpose of anti-tumor by activating the immune cells in the body.However,they also cause a series of immune-related adverse effects while expanding the immune against tumor.Especially,ICIs-related myocarditis has attracted people’s attention due to its high mortality.This review summarizes the epidemiology,mechanism,potential biomarkers for predicting the treatment response and diagnosis of PD-1 ICIs-related myocarditis.
作者
李松珊
曹慧丽
赵娅敬
代虎威
曾康
温泽宇
杨滨
LI Song-shan;CAO Hui-li;ZHAO Ya-jing;DAI Hu-wei;ZENG Kang;WEN Ze-yu;YANG Bin(Department of Second Clinical Medicine,Shanxi Medical University,Taiyuan 030000,China;Department of Cardiovascular Medicine,the Second Hospital of Shanxi Medical University,Taiyuan 030000,China)
出处
《中国心血管病研究》
CAS
2022年第7期662-666,共5页
Chinese Journal of Cardiovascular Research
基金
山西省卫生健康委科研课题(2020071)。
